Can a Two-Drug bladder wash beat cancer recurrence?

NCT ID NCT07747740

Recruiting now Disease control Sponsor: Blokhin's Russian Cancer Research Center Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests two different drug combinations given directly into the bladder for people with a type of bladder cancer that has not responded to the standard BCG therapy. Participants are randomly assigned to receive either gemcitabine plus docetaxel or gemcitabine plus mitomycin C. The goal is to see which combination better prevents the cancer from coming back or progressing over a year, while also checking safety and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sequential intravesical gemcitabine plus docetaxel, compared with sequential intravesical gemcitabine plus mitomycin C
What this could lead to: If successful, this could offer a bladder-sparing alternative to cystectomy for patients with BCG-unresponsive bladder cancer, potentially improving survival and quality of life.
What could go wrong: This is a phase II trial, so results are preliminary. The treatments may not prove more effective than existing options, and there are risks of side effects from chemotherapy delivered directly into the bladder.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCG-UNRESPONSIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCG-UNRESPONSIVE BLADDER CANCER NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Locations

N.N. Blokhin National Medical Research Center of Oncology
RECRUITING

Moscow, Moscow, 115522, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.